|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a previous work, we showed that in TNBC miR-210 is expressed in tumor cells and also in the tumor microenvironment (TME), particularly in inflammatory CD45-LCA positive cells.
|
31787032 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A diagnosis of HS was made based on the results of a panel of immunohistochemical stains that revealed positivity of leukocyte common antigen, CD4, CD163, and HLA-DR. At the time of resection, the tumor grew rapidly to 12 × 6.5 × 5 cm in size in 2 months.
|
31567137 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These spatial light-patterns can be automatically configured to profile (1) "tumor-only" cells plus "tumor-microenvironment-only" cells; (2) unique cell types and rare cell features (e.g., macrophages, CD8, CD3, CD45, PD-L1 on macrophages, PD-L1 on tumors, etc.); (3) spatial gradients around cell-features or tumor features (e.g., excluded boundaries); (4) hypothesis-free spatial grids; (5) simple hand-selected geometric areas (e.g., free-hand software-based "drawing" on tissue regions); and (6) or any combination of the above modalities.
|
31502169 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our data suggest that the Gal-1 aptamer suppresses tumor growth by blocking the interaction between Gal-1 and CD45 to rescue T cells from apoptosis and restores T cell-mediated immunity.
|
31778957 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Formalin-fixed, paraffin-embedded breast cancer samples were analysed on tissue microarrays using mIF, which combined phospho-histone H3 (pHH3) expression with cytokeratin (CK) and leukocyte common antigen (CD45) expression to identify tumour and immune cells, respectively.
|
31410680 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The prognostic value of programmed cell death ligand 1 (PD-L1) expression in tumor cells and tumor infiltrating lymphocytes (TILs) and the percentage of CD3-, CD20-, CD45- and CD68-positive cells, were also investigated.
|
30735815 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To better understand the correlation between BRCA1/2 mutations and the immune phenotype in prostate cancer, we characterized the immune infiltrate of eight BRCA2-mutated tumors in comparison with eight BRCA1/2 wild-type patients by T-cell receptor sequencing and immunohistochemistry for CD45, CD4, CD8, FOXP3, and CD163.
|
31549213 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study examined the influence of CD45-positive cells in liver parenchyma and primary tumors on cumulative survival.
|
30842149 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we used single-cell RNA sequencing to define the CD45+ immune cell populations at different time points within B16F10 murine melanoma tumors growing in either wild-type or miR-155 T cell conditional knockout (TCKO) mice. miR-155 was required for optimal T cell activation and reinforced the T cell response at the expense of infiltrating myeloid cells.
|
30721153 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While the palladium-based barcoding affected the stability of several antigens, the staining with two differently labeled CD45 antibodies was suitable for cells isolated from a patient's blood and tumor.
|
30886872 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
After the treatment period, the tumor tissues were weighed and harvested for mRNA and protein isolation. qPCR and Western blotting were used to evaluate the expression of cancer stemness markers (epithelial cell adhesion molecule [EpCAM], cluster of differentiation [CD13], CD90, aldehyde dehydrogenase 1 [ALDH1], CD44, and CD45), totipotency factors (sex determining region Y-box 2 [Sox2], Nanog, and octamer-binding transcription factor 4 [Oct4]), and genes involved in the Notch, Wnt/<i>β</i>-catenin, Hedgehog, and Hippo signaling pathways.
|
31341493 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the combination elicited a robust systemic and tumor-specific immune response with (a) increased percentages of systemic and tumor infiltrated CD45+CD11b+ cells, (b) increased levels of myeloperoxidase (MPO), (c) increased antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP), (d) decreased percentage of immune regulatory cells (CD8+CD69+ cells), and (e) reduced circulating levels of immunosuppressive tMUC1.
|
31114758 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This is the first study which separately analyzes peritumoral stroma and tumor core area in laryngeal squamous cell carcinoma in terms of CD45, CD11b, CD3, MMP-9 and COX-2 expression.
|
29492204 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Laser capture microscopy combined with gene expression profiling reveals that the expression of interferon-responsive genes is up-regulated in PDPN-expressing cells at the tumor invasive front, which are exposed to CD45-positive inflammatory cells.
|
29458011 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of CD45 Phosphatase Activity Induces Cell Cycle Arrest and Apoptosis of CD45<sup>+</sup> Lymphoid Tumors Ex Vivo and In Vivo.
|
29555821 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor OGN expression levels were positively associated with CD3, CD8, and PTPRC expressions in the training and testing sets from TCGA, respectively.
|
30037719 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In oropharyngeal carcinomas, HPV-positive tumors showed a higher transcriptional CD45 expression than HPV-negative tumors.
|
29177949 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients who had their tumor sequenced by either FoundationOne (<i>n</i> = 13) or the institutional T200/T200.1 panels (<i>n</i> = 7) were included in this study.
|
29731991 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A single dose of rituximab during the primary tumor heterotransplantation process reduced the incidence of CD45-positive cells in subsequent PDX lines from 86.3% (n = 117 without rituximab) to 5.6% (n = 160 with rituximab), and the lymphoma rate declined from 11.1% to 1.88%.
|
28658648 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we demonstrated that the <i>in vivo</i> injection of recombinant human IL-15 (200 µg/kg) or murine IL-15 (3 µg/kg) to tumor-bearing NOD-<i>SCID-IL2Rg-/-</i> (NSI) mice resulted in increased tumor progression and CD45+ CD11b+ Gr-1+ CD215+ cell expansion in the tumors and spleen.
|
29255466 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effectiveness of magnetic‑activated cell sorting (MACS) for tumor‑cell enrichment, through the depletion of CD45+ leukocytes in PBMC samples, was also assessed.
|
28849093 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
[PtCl<sub>4</sub>(en)] managed to increase presence of CD45+ leukocytes, including F4/80+ macrophages, CD11c+ dendritic cells, CD4+ helper and CD8+ cytotoxic T cells (CTLs) in the lungs, cytotoxic NK, NKT and CTLs in the spleens of tumor bearing mice, resulting with reduction of metastatic lesions in the lungs, indicating its potential to stimulate anti-tumor immune response in vivo.
|
28421385 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MMP9, CD44, DLL4, FOXP1, MERTK, and PTPRC genes were found more expressed in tumors re-growing after cisplatinum treatment than in untreated tumors.
|
26910918 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Statistical performance of image cytometry for DNA, lipids, cytokeratin, & CD45 in a model system for circulation tumor cell detection.
|
28608985 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite heterogeneous dynamics of clinical tumor regression, residual tumors displayed highly recurrent transcriptomic alterations and enriched processes, which were also observed in MAPKi-selected cell lines (implying tumor cell-intrinsic reprogramming) or in bulk mouse tumors (and the CD45-negative or CD45-positive fractions, implying tumor cell-intrinsic or stromal/immune alterations, respectively).
|
28864476 |
2017 |